A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

mRNA-1273

Sterile liquid for injection

Trial Locations (15)

10032

Colombia University Medical Center, New York

11030

Northwell Health, Manhasset

19104

Hospital of The University of Pennsylvania, Philadelphia

30309

Piedmont Transplant Institute, Atlanta

33606

Tampa General Medical Group, Tampa

44195

Cleveland Clinic Hospital, Cleveland

45219

University of Cincinnati, Cincinnati

68198

University of Nebraska Medical Center, Omaha

85206

Aventiv Research Inc, Mesa

92123

California Institute of Renal Research, San Diego

98195

University of Washington Medical Center, Seattle

06519

Yale University School of Medicine, New Haven

02115

Brigham and Women's Hospital, Boston

01655

University of Massachusetts Medical School, Worcester

02903

Rhode Island Hospital, Providence

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY